Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Linden Lake Venture Capital specializes in founding and investing in biotechnology companies focused on new molecular medicines. The firm combines expertise in biotechnology, medical knowledge, legal acumen, and private equity investment experience. They target early-stage investments, particularly in pre-seed, seed, and Series A rounds.
Linden Lake Venture Capital invests in early-stage biotechnology companies engaged in pre-clinical and phase I technologies. Their investment focus includes novel therapeutic biologics, gene/nucleic acid-based therapies, cell/regenerative therapies, and platforms for personalized medicine.
Notable portfolio companies include Vesigen Therapeutics, which develops scalable extracellular vesicle delivery technology, and AexeRNA Therapeutics, acquired by BioNTech SE in October 2023.
Submit your pitch through their website's contact form for consideration.
As of October 2023: Linden Lake Venture Capital celebrated the acquisition of AexeRNA Therapeutics by BioNTech SE, marking a significant exit for the firm.
Yes, Linden Lake Venture Capital often leads investment rounds in the companies they back, particularly in early-stage biotech.
The firm is open to follow-on investments, especially in companies that demonstrate significant progress and potential in their therapeutic developments.
Specific fund size details are not publicly available, but the firm focuses on early-stage investments in the biotechnology sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.